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ABSTRACT
Knowledge and investigation of therapeutic targets
(responsible for drug efficacy) and the targeted
drugs facilitate target and drug discovery and valid-
ation. Therapeutic Target Database (TTD, http://
bidd.nus.edu.sg/group/ttd/ttd.asp) has been de-
veloped to provide comprehensive information
about efficacy targets and the corresponding ap-
proved, clinical trial and investigative drugs. Since
its last update, major improvements and updates
have been made to TTD. In addition to the signifi-
cant increase of data content (from 1894 targets and
5028 drugs to 2025 targets and 17816 drugs), we
added target validation information (drug potency
against target, effect against disease models and
effect of target knockout, knockdown or genetic
variations) for 932 targets, and 841 quantitative
structure activity relationship models for active com-
pounds of 228 chemical types against 121 targets.
Moreover, we added the data from our previous
drug studies including 3681 multi-target agents
against 108 target pairs, 116 drug combinations with
their synergistic, additive, antagonistic, potentiative
or reductive mechanisms, 1427 natural product-
derived approved, clinical trial and pre-clinical drugs
and cross-links to the clinical trial information page
in the ClinicalTrials.gov database for 770 clinical trial
drugs. These updates are useful for facilitating
target discovery and validation, drug lead discovery
and optimization, and the development of multi-
target drugs and drug combinations.
INTRODUCTION
Modern drug discovery is primarily focused on the search
or design of drug-like molecules, which selectively interact
and modulate the activity of one or a few selected thera-
peutic targets (1–3). One challenge in drug development is
to choose and explore promising targets from a growing
number of potential targets (4). Target selection and val-
idation are important not only for achieving therapeutic
efﬁcacy but also for increasing drug development odds,
given that few innovative targets have made it to the
approved list each year [12 innovative targets in 1994–
2005 (5) and 10 new human targets in 2006–2010 (6) for
small molecule drugs]. Apart from target selection and
validation, drug discovery efforts can be facilitated by
enhanced knowledge of bioactive molecular scaffolds
(7,8), structure–activity relationships (9), multi-target
agents (10,11) and synergistic drug combinations (12)
against selected target or multiple targets, and information
about the sources of drug leads such as the species origins
of natural product-derived drugs (13).
Internet resources such as Therapeutic Target Database
(TTD) (14,15) and DrugBank (16) provide comprehensive
information about the targets and drugs in different de-
velopment and clinical stages, which are highly useful for
facilitating focused drug discovery efforts and pharma-
ceutical investigations against the most relevant and
proven targets (17–19). In addition to the update of
these databases by expanded target and drug data
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drug discovery efforts can be further enhanced by adding
additional information and knowledge derived from the
target and drug discovery processes. Therefore, we
updated TTD by both signiﬁcantly expanding the target
and drug data and adding new information about target
validation, quantitative structure–activity relationship
(QSAR) models of a variety of molecular scaffolds
active against selected targets and speciﬁc types of drugs
(multi-target drugs and natural product-derived drugs)
and drug combinations (synergistic, additive, antagonistic,
potentiative and reductive combinations).
The signiﬁcantly expanded target and drug data cover
364 successful, 286 clinical trial, 44 discontinued clinical
trial and 1331 research targets, and 1540 approved, 1423
clinical trial, 345 discontinued clinical trial, 165 pre-
clinical and 14853 experimental drugs linked to their
primary targets (14170 small molecule and 652 anti-
sense drugs with available structure and sequence data)
(Table 1). These are compared to 348 successful,
249 clinical trial, 43 discontinued clinical trial and 1254
research targets, and 1514 approved, 1212 clinical trial
and 2302 experimental drugs in our last update (15). To
facilitate the access of clinical trial information of the
clinical trial drugs, cross-links to the relevant page in
ClinicalTrials.gov database are provided for 770 clinical
trial drugs. The newly added target validation data
includes the experimentally measured potency of 11810
drugs against 915 targets, the observed potency or effects
of 497 drugs against disease models (cell lines, ex vivo,
in vivo models) linked to 393 targets, and the observed ef-
fects of target knockout, knockdown or genetic variations
for 307 targets (Table 2). The QSAR data consists of 841
QSAR models for active compounds of 228 chemical types
against 121 targets (Table 2).
Moreover, we added the data partly derived from our
previous studies of multi-target drugs (20,21), drug com-
binations (12) and natural product derived drugs (13)
(Table 2). The multi-target drug data is composed of
3681 multi-target agents active against 108 target pairs
together with their potencies against the target pairs.
The drug combination data includes 72, 14 and 4
pharmacodynamically synergistic, additive and antagon-
ist combinations, and 19 and 7 pharmacokinetically
potentiative and reductive combinations together with
their mode of actions and combination mechanisms.
The natural product-derived drug data includes the
drug names and their species origins and species
families for 939 approved, 369 clinical-trial and 119
pre-clinical drugs.
NEW TARGET AND DRUG DATA COLLECTION
Additional target and drug data, including the approved,
clinical trial and experimental drugs and their primary tar-
gets, were collected by using the same methods described
in our previous publications (14,15). In particular, all
TTD targets are primary targets (i.e. efﬁcacy targets) dir-
ectly responsible for the claimed therapeutic efﬁcacies (in
Table 2. Summary and statistics of newly added data in 2012 version
of TTD
Data Category Number of
Information
Target validation data
Experimentally measured potency of drugs against targets
Number of drugs 11810
Number of targets 915
Drug potency against disease model (cell-lines, ex vivo, in vivo
models)
Number of drugs 497
Number of targets 393
The observed effects of target knockout, knockdown or genetic
variations
Number of targets 307
QSAR models
Number of QSAR models 841
Number of Chemical types 228
Number of targets 121
Structure and potency information of multi-target agents against
target pairs
Number of multi-target agents 3681
Number of target pairs 108
Drug combination data
Pharmacodynamically synergistic drug combinations
Number of drug combinations due to
anti-counteractive actions
22
Number of drug combinations due to complementary
actions
30
Number of drug combinations due to facilitating
actions
20
Number of pharmacodynamically additive drug
combinations
14
Number of pharmacodynamically antagonistic drug
combinations
4
Number of pharmacokinetically potentiative drug
combinations
19
Number of pharmacokinetically reductive drug
combinations
7
Natural product-derived drugs and their species origins
Number of natural product-derived approved drugs 939
Number of natural product-derived clinical trial drugs 369
Number of natural product-derived pre-clinical drugs 119
Table 1. Statistics of drug targets, drugs and structure and sequence
data in TTD database
Data Category 2012
update
2010
update
Statistics of drug targets
Number of all targets 2025 1894
Number of successful targets 364 348
Number of clinical trial targets 286 249
Number of discontinued targets 44 43
Number of research targets 1331 1254
Statistics of drugs
Number of all drugs 17816 5028
Number of approved drugs 1540 1514
Number of clinical trial drugs 1423 1212
Number of discontinued drugs 345 274
Number of pre-clinical drugs 165 142
Number of experimental drugs 14853 2302
Statistics of drugs with available structure or sequence data
Number of small molecular drugs with
available structure
14170 3382
Number of antisense drugs with available
sequence data
652 649
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responding drugs as conﬁrmed by biochemical assay and
strong cell based and/or in vivo evidence linking the target
to drug (15,17,22). The status of approved drugs and
clinical trial drugs is up-to-date as of December 2010.
The discontinued clinical trial drugs are based on the re-
port from US National Institutes of Health (NIH, http://
clinicaltrials.gov/). The discontinued clinical trial targets
are those clinical trial targets that no longer have an active
clinical trial drug at the end of 2010. Pre-clinical drugs are
drug candidates that have passed discovery stages and
started such pre-clinical studies as safety, PK/ADME,
active pharmaceutical ingredient preparation and formu-
lation (23). The newly added experimental drugs were se-
lected based on a potency cut-off value of 20mM against
their targets.
TARGET VALIDATION DATA
Target validation has been routinely performed to demon-
strate the functional role of the potential target in disease
phenotype and the ability of drug-like molecules to
modulate the activities of the target to achieve therapeutic
efﬁcacies (24,25). Target validation normally requires the
determination that the target is expressed in the disease-
relevant cells/tissues, it can be directly modulated by a
drug or drug-like molecule with adequate potency in bio-
chemical assay, and that target modulation in cell and/or
animal models ameliorates the relevant disease phenotype
(24,26). In vivo target validation has been conducted
mostly in knockout mice, transgenetic in vivo models, and
also in RNA interference, antibody and antisense treated
in vivo models (26,27). We therefore searched the PubMed
database (28) to collect from literature three types of
target validation data: experimentally determined potency
of drugs against their primary target or targets, observed
potency or effects of drugs against disease models (cell
lines, ex vivo, in vivo models) linked to their primary target
or targets, and the observed effects of target knockout,
knockdown, transgenetic, RNA interference, antibody or
antisense-treated in vivo models. Target validation data
can be retrieved by clicking the ‘Target Validation’ ﬁeld
in the TTD home page, which lead to the TTD target val-
idation information page wherein a user can select the rele-
vant data for a particular target from the target name list
(Figure 1).
QUANTITATIVE STRUCTURE–ACTIVITY
RELATIONSHIP MODELS AGAINST
SPECIFIC TARGET
QSAR models for active compounds against many differ-
ent targets have been developed and explored for drug
lead discovery and optimization (9,29). These models elu-
cidate the chemical characteristics favorable to the modu-
lation of the activity of speciﬁc target at sufﬁcient potency
by establishing quantitative correlations between molecu-
lar properties and biological activities (e.g. 50% inhibition
concentration or binding afﬁnities) (30). In drug lead op-
timization projects, QSAR models against speciﬁc target
can be recursively developed and used for guiding the
design or search of more potent compounds or com-
pounds with more desired drug-like properties as the
new activity or drug-like property data from newly
synthesized compounds become available (9,29).
Therefore, knowledge of developed QSAR models for
different molecular scaffolds active against different
targets is highly useful for facilitating further drug
Figure 1. The target validation information page of TTD.
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the QSAR models, we have collected in our previous
analysis of QSAR models of bioactive compounds (31),
we searched PubMed database (28) to collect 309 papers
that describe 841 ligand-based QSAR models for active
compounds of 228 chemical types against 121 targets.
While there are also a high number of papers
describing receptor-based QSAR models, these models
were not included in TTD because they are not easily
displayed in explicit form in a database setting without
obtaining copyrights from the relevant journals. The
included QSAR models can be accessed by clicking the
‘QSAR Models’ ﬁeld in the TTD home page, which
lead to the TTD QSAR model page wherein a user can
select the relevant model for a particular chemical class
against a speciﬁc target either from the target name list or
the chemical type list (Figure 2). The retrieved QSAR
model page (Figure 3) contains the information about
target and ID, target species, chemical type, compound
mode of action, QSAR models, the molecular descriptors
in the QSAR models, references and hyperlinks to the
molecular descriptor computation web servers MoDeL
(32) and e-dragon (33).
MULTI-TARGET AGENTS
Therapeutic agents directed at an individual target fre-
quently show reduced efﬁcacies, undesired safety proﬁles
and drug resistances due to network robustness,
redundancy, cross-talk, compensatory and neutralizing ac-
tions, anti-target and counter-target activities (34–36).
Multi-target agents directed at selected multiple targets
have been increasingly explored for enhanced therapeutic
efﬁcacies, improved safety proﬁles and reduced resistance
activities by simultaneously modulating the activity of a
primary target and the counteractive elements (3,37,38). In
addition to the multi-target agents we have collected in
our previous studies of multi-target drugs (20,21), we fur-
ther searched PubMed (28) using such keywords as ‘multi-
target’, ‘dual target’ and ‘dual inhibitor’. Multi-target
agent against a target pair refers to a compound active
against both targets at potency values of 20mM regard-
less of their possible activities against other targets. The
3D structures of these multi-target agents were generated
by using CORINA (39) from the 2D structures manually
drawn based on the literature provided structures or
the structures found in such chemical databases as
BindingDB (40), ChEMBL (41) and PubChem (28).
These multi-target agents can be retrieved by clicking
the ‘Multi-Target Agents’ ﬁeld in the TTD home page,
which lead to the TTD multi-target agents page wherein
a user can download the multi-target agents against a
speciﬁc target pair from the target pair list (Figure 4).
DRUG COMBINATIONS
Apart from multi-target agents, drug combinations have
also been extensively explored for enhanced therapeutic
Figure 2. QSAR model page of TTD.
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activities (12,38,42). When two drugs produce the same
broad therapeutic effect, their combination collectively
produces the same effects of various magnitudes in con-
trast to the summed response of the individual drugs. A
drug combination is pharmacodynamically synergistic,
additive or antagonistic if the effect is greater than,
equal to or less than the summed response of the individ-
ual drugs (43). Drug combinations may also produce
pharmacokinetically potentiative or reductive effects such
that the therapeutic activity of one drug is enhanced or
reduced by another drug via regulation of the ﬁrst drug’s
ADME (43). In our earlier studies of drug combinations
(12), we have searched PubMed (28) to select those
literature-reported drug combinations evaluated by rigor-
ous combination analysis methods and with known mo-
lecular mechanism of combination retrievable from
PubMed by using combinations of the keywords ‘drug
combination’, ‘drug interaction’, ‘multi-drug’, ‘additive’,
‘antagonism’, ‘antagonistic’, ‘infra-additive’, ‘potentiated’,
‘potentiative’, ‘potentiation’, ‘reductive’, ‘supra-additive’,
‘synergism’, ‘synergistic’ and ‘synergy’.
All major classes of drug combinations can be further
divided into groups of speciﬁc action types (12).
Pharmacodynamically synergistic drug combinations can
be divided into three groups: each one with anti-
counteractive, complementary and facilitating actions, re-
spectively. Anti-counteractive actions reduce network’s
counteractive activities against a drug’s therapeutic effect.
Complementary actions positively regulate a target or pro-
cess by interactions with multiple target/pathway sites,
different target subtypes and states, and competing mech-
anisms (3). Facilitating actions are secondary actions of
one drug in enhancing the activity or level of another
drug. Pharmacodynamically additive drug combinations
can be divided into two groups, one with equivalent or
overlapping actions, and the other with independent
actions of the drugs involved. Pharmacodynamically an-
tagonistic drug combinations can also be divided into two
groups, one with mutually interfering actions at the same
target, another with mutually counter-active actions at
different targets of related pathways that regulate the
same target. Pharmacokinetically potentiative drug com-
binations can be divided into three groups, each one with
positive modulation of drug transport or permeation, drug
distribution or localization and drug metabolism, respect-
ively. Pharmacokinetically reductive drug combinations
can be divided into three groups, each one with negative
modulation of drug transport or permeation, drug distri-
bution or localization and drug metabolism, respectively.
Figure 3. The page of the QSAR models for a particular chemical class against a speciﬁc target in TTD.
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isms can be accessed by clicking the ‘Drug Combinations’
ﬁeld in the TTD home page, which lead to the TTD drug
combinations page wherein a user can download the
relevant drug combination data from the drug combin-
ation type list (Figure 5).
NATURAL PRODUCT-DERIVED DRUGS
Many of the approved and clinical trial drugs are derived
from natural products (44,45). Although drug discovery
focus has been shifted from natural products to synthetic
chemicals, natural product-derived drugs still constitute a
substantial percentage of recently approved drugs (26% of
the 46 FDA approved new molecular entities in 2009–2010
are natural product derived) (13). There is a renewed
interest in natural products as sources for drug discovery
(46). Knowledge of the natural sources of drugs, the
species origins of the natural product-derived approved,
clinical trial and pre-clinical drugs, are highly useful for
facilitating the search and development of new drug leads.
In our earlier analysis of the species origins of natural
product-derived drugs, we have collected the species ori-
gins and species families of natural product-derived
approved, clinical trial and pre-clinical drugs (13).
The species-origins of these drugs have been identiﬁed
as follows. First the literature-reported approved drugs
(44), clinical trial (45,47) and pre-clinical (13) drugs of
natural origin were evaluated with respect to the drugs
in our TTD database (15) to check their current approval
or clinical trial status. Then the species-origin of every
drug was searched from books, review and regular articles
by using combinations of such keywords as drug name
and alternative names, species, natural product and nature.
The species-origin of a drug is conﬁrmed if it is speciﬁcally
mentioned that it ‘originates from’, ‘derived from’, ‘iso-
lated from’ or ‘comes from’ a species or species-group (e.g.
genus or family). For drugs of semi-synthetic derivatives,
mimics and peptidomimetics, their parent natural product
leads were ﬁrst searched followed by the search of host
Figure 4. Multi-target agents page of TTD.
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Figure 5. Drug combination page of TTD.
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families of the host-species of these drugs as well as all
the known species-families in the nature are from the
NCBI taxonomy database (28). These natural product-
derived drugs and their species origins and families can
be retrieved by clicking the ‘Nature-Derived Drugs’ ﬁeld
in the TTD home page, which lead to the TTD natural
product-derived drugs page wherein a user can download
the relevant data from the drug status list (Figure 6).
REMARKS
A goal in updating TTD is to make it into a more useful
target and drug discovery resource in complement to other
related databases. Continuous efforts will be made to
provide the latest and comprehensive information about
the primary (efﬁcacy) targets of approved, clinical trial,
pre-clinical and experimental drugs and other relevant
data for these drugs. Intensive efforts in drug and target
discovery have led to and will continue to enable the gen-
eration of new information, knowledge and models from
existing targets (18), drugs (9,29,48,49), multi-target drugs
(20) and drug combinations (12,38,42). Drug discovery
efforts have beneﬁted and are continuing to be beneﬁted
from the exploration of multiple lead sources including
synthetic chemicals (1–3), biologics (50–53) and natural
products (13,44,45). Inclusion of these information, know-
ledge and models into TTD and other databases will
further enable these databases to better serve the drug
discovery and research communities in their efforts for
discovering new targets and new drugs from different
sources.
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